Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.56 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010798 | 0.92 | TDP2 (0.56) | TDP2RNASEH1SRD5A1ERN1PGR | |
| SCHEMBL23511723 | 0.74 | RNASEH1 (0.62) | RNASEH1 | |
| SCHEMBL25060904 | 0.73 | RNASEH1 (0.62) | TDP2RNASEH1 | |
| SCHEMBL18010843 | 0.72 | TDP2 (1.00) | TDP2 | |
| SCHEMBL3358267 | 0.69 | RNASEH1 (1.00) | RNASEH1 | |
| SCHEMBL5873706 | 0.69 | TDP2 (0.70) | TDP2PGR | |
| SCHEMBL8812836 | 0.68 | TDP2 (0.45) | TDP2SRD5A1ERN1PGRKEAP1 | |
| SCHEMBL3780448 | 0.68 | AADAT (0.56) | TDP2 | |
| SCHEMBL18010809 | 0.67 | TDP2 (1.00) | TDP2 | |
| SCHEMBL20777907 | 0.63 | ACHE (0.58) | RNASEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243149-A1 | NOVEL ANTI-VIRAL THERAPEUTIC | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243149-A1 | NOVEL ANTI-VIRAL THERAPEUTIC | RNASEH1, DNASE1L3, DNASE1 | TDP2 660/4885RNASEH1 1/4885SRD5A1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.